. Author manuscript; available in PMC: 2021 Mar 1.

Published in final edited form as: J Immunol. 2020 Aug 3;205(5):1331–1344. doi: 10.4049/jimmunol.1901431

TABLE 2.

Mutations associated with changes in N-glycosylation in SIV vaccine

		VL (SIV RNA copies/ml)		original		vaccine Env			SIV543 Env
vaccinee	days post treatment	SIV239 gag	SIV543 gag	vaccine	new NGS (a.a)^a	lost NGS (a.a)	total #NGS	deglycosylation^b

Mm0301	8	10125	ND^c	Δ5G	417		19	−4	ND
				Δ5G	417		19	−4	ND
	21	340000	ND	Δ5G	148		19	−4	ND
				Δ5G	417		19	−4	ND
				Δ5G	148		19	−4	ND
				Δ5G	148, 417		20	−3	ND

Mm0303	15	173750	258125	Δ5GV1	417	247	18	−5	D^d
				Δ5GV1	417	247	18	−5	D
				Δ5GV1	417	247	18	−5	D
				Δ5GV1	417	247	18	−5	D
				Δ5GV1	417	247	18	−5	D
				Δ5GV1	417	247	18	−5	D
				Δ5GV1	417	247	18	−5	D
				Δ5GV1	417	247	18	−5	D

Mm515	8	1406250	ND	Δ3G	148, 248	202	21	−2	ND
			ND	Δ3G	148, 248	202	21	−2	ND
			ND	Δ3G	148, 248	202	21	−2	ND

The position of new N-glycosylation site (NGS: NXS/T) in amino acid residue in Env (a.a) of the vaccine virus.

Number of N-glycosylation sites mutated to reduce N-glycosylation sites relative to SIVmac239.

Not detected.

Detected.